Group 1 - The core viewpoint of the news is that Beijing Ruimait Medical Technology Co., Ltd. has seen a stock price increase of 5.01%, reaching 88.86 CNY per share, with a total market capitalization of 7.962 billion CNY [1] - The company specializes in the research, production, and sales of medical devices and consumables in the respiratory health field, primarily targeting patients with obstructive sleep apnea hypopnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The revenue composition of the company includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Group 2 - From the perspective of fund holdings, Jin Xin Fund has a significant position in Ruimait, with its Jin Xin Value Selection Mixed A Fund reducing its holdings by 17,000 shares, now holding 15,000 shares, which constitutes 4.2% of the fund's net value [2] - The Jin Xin Value Selection Mixed A Fund has achieved a year-to-date return of 54.11%, ranking 664 out of 8140 in its category [2] - The fund manager Liu Shang has a tenure of 88 days with a total asset scale of 1.09 million CNY, while manager Tan Zhiming has a tenure of 223 days with a total asset scale of 1.41 million CNY [3]
瑞迈特股价涨5.01%，金信基金旗下1只基金重仓，持有1.5万股浮盈赚取6.36万元